Drug Database
UN

unspecified allergy vaccine (Staloral)

✓ Approved

Stallergenes · therapeutic agent

What is unspecified allergy vaccine?

unspecified allergy vaccine is a therapeutic agent developed by Stallergenes. It is approved for therapeutic indications via injectable (others) or oral (po) or subcutaneous injection or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesStaloral
CompanyStallergenes
RouteInjectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
StatusApproved

Therapeutic Indications

unspecified allergy vaccine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

Related Research Articles

PubMedActa clinica Belgica2026-07-25

Belgian consensus-based recommendations on the management of hospitalized patients with a penicillin allergy label.

Schrijvers Rik R, Cox Janneke J, Pirson Françoise F, Toscano Alessandro A et al.

Penicillin allergy labels are common among hospitalized adults and are frequently inaccurate, potentially leading to inappropriate antibiotic use and avoidable harm. This Belgian consensus-based recommendation aims to provide a pragmatic framework for the management of penicillin allergy labels in hospitalized adults (>18 years), with particular emphasis on distinguishing low- to high-risk labels. Recommendations were developed through a structured, multidisciplinary expert consensus process and are presented as a stepwise clinical algorithm. The recommendations highlight a structured approach to evaluate reactions through a series of questions, delineating between severe and non-severe signs. It offers a pragmatic algorithm for managing low-risk penicillin allergy labels through re-administration procedures while ensuring emergency preparedness for rare adverse reactions. Comparisons with existing protocols revealed differences in approaches to delabeling, referral criteria for allergy evaluation, and liberalization of antibiotic choices based on reaction severity, timelines, and individual patient risk factors. The recommendation favors a patient-centric risk-assessment approach, offering distinctions between severe and non-severe reactions and includes precautions based on reaction types and timelines. This consensus-based recommendation offers a structured approach to managing penicillin allergy labels in hospitalized adults.

PubMedPediatric investigation2026-07-25

Bilateral infantile Frey syndrome mimicking food allergy: A case report.

Ohara Yuki Y, Fujita Mayumi M, Inuo Chisato C

PubMedClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026-07-25

Risk of Systemic Reactions After Repeated Large Local Reactions in Hymenoptera Venom Allergy: A Real-World Study.

Martini Matteo M, Apricena Antonietta A, Buti Elena E, Bignardi Donatella D et al.

PubMedJournal of the International AIDS Society2026-07-25

Behavioural and Structural Determinants of Mpox Vaccine Awareness and Uptake Among People With HIV in the Dominican Republic: A Cross-Sectional Study.

Paulino-Ramirez Robert R, Matias Wilfredo R WR, Chaumette Alexandre A, Lora-Rodríguez Hector H et al.

Mpox disproportionately affects people with HIV (PWH), yet little is known about mpox vaccine awareness and uptake in low- and middle-income countries. We evaluated mpox-related knowledge, attitudes and practices (KAP) among PWH in the Dominican Republic to identify determinants of vaccine awareness and uptake. We conducted a cross-sectional online survey of 98 PWH recruited through HIV clinics, community-based organizations and social networks (January-May 2025). The questionnaire assessed sociodemographic characteristics, mpox-related KAP, structural barriers and vaccination status. Univariable and multivariable logistic regression were used to examine factors associated with mpox vaccine awareness. Half of the participants (49/98) were aware of the mpox vaccine. Individuals aged 31-40 years had significantly lower odds of awareness compared with those aged 21-30 years. Despite high levels of formal education, 79% rated their mpox knowledge as low, and most perceived minimal personal risk. Among participants aware of the vaccine, 71% had been vaccinated. Structural barriers, including inconvenient site locations and logistical challenges, were frequently reported, even among vaccinated individuals, indicating that access limitations rather than hesitancy were the dominant constraints. Trust in vaccinating organizations was high overall, and healthcare providers and community organizations were the primary sources of vaccine information. Peer and community influence emerged as notable facilitators of uptake, while lack of reliable information and concerns about vaccine safety contributed to hesitancy. Mpox vaccine awareness among PWH in the Dominican Republic was low, but willingness to vaccinate was high when individuals were informed and able to access services. Strengthening mpox preparedness will require expanding accessible vaccination sites, improving disease-specific health literacy, and leveraging trusted community and clinical networks. Integrating mpox vaccination into routine HIV care delivery and enhancing community-led outreach may substantially improve uptake in this and similar low-middle income countries (LMIC) settings.

PubMedPneumonia (Nathan Qld.)2026-07-25

Pneumococcal pneumonia in adults - re-emergence of vaccine serotypes: a prospective multicenter cohort study in Germany, 2020-2023.

Bahrs Christina C, Rose Norman N, Barten-Neiner Grit G, Fleischmann-Struzek Carolin C et al.

The main burden of non-invasive pneumococcal diseases in adults is largely due to community-acquired pneumonia (CAP). This study aimed to investigate the distribution and dynamics of pneumococcal vaccine serotypes and to determine the proportion of CAP cases attributable to serotypes covered by 13-valent conjugate vaccine (PCV13), the 20-valent conjugate vaccine (PCV20), and the 23-valent polysaccharide vaccine (PPV23) among adults in Germany from 2020 to 2023. In this prospective multicenter cohort study, we analyzed all adult patients with CAP enrolled between January 1, 2020, and December 31, 2023, at 26 centers in Germany who provided urine samples for serotype-specific urine antigen detection (SSUAD) testing. Annual trends of pneumococcal vaccine serotypes from 2020 to 2023 were calculated for all patients and patient groups at risk using cluster-robust generalized linear models with heteroscedasticity-consistent standard errors. Of the 2,028 patients with all-cause CAP, 1,504 (1,008 patients aged ≥ 60 years, 373 younger patients with at least one comorbidity) had urine samples analyzed with SSUAD tests. Overall proportion of vaccine-type pneumococcal pneumonia among all-cause CAP for PCV13, PCV20, and PPV23 serotypes was 5.41% (95% CI 4.12-7.06%), 8.11% (95% CI 6.35-10.31%), and 8.31% (95% CI 6.27-10.93%), and serotype 3 was the most prevalent serotype (52 cases). Among patients aged ≥ 60 years, an increasing annual trend was observed for serotype 3 (OR 1.84, 95% CI 1.01-2.67), PCV13 (OR 1.89, 95% CI 0.89-2.89), PCV20 (OR 1.57, 95% CI 0.99-2.14), and PPV23 serotypes (OR 1.47, 1.04-1.91). The findings demonstrate that vaccine serotypes, particularly serotype 3, continued to circulate and reemerged among older adults with CAP in Germany.

PubMedJournal of gastrointestinal cancer2026-07-25

Mortality Trends of Biliary Tract Cancers in the United States, 1999-2023: a CDC-WONDER Analysis.

Chen Jianguo J, Yang Guangwei G, Sun Xiaodong X

Biliary tract cancers (BTCs) comprise a heterogeneous group of malignancies, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, ampulla of Vater tumors, and other or unspecified BTCs. We examined population-level BTC mortality trends and disparities in the US from 1999 to 2023. Deaths among adults aged ≥ 35 years were obtained from CDC WONDER using ICD-10 codes C22.1, C23, C24.0, C24.1, C24.8, and C24.9. AAMRs per 100,000 were calculated and assessed using Joinpoint regression, with stratification by sex, race/ethnicity, age, census region, and urbanization level. Urbanization analyses used standardized data through 2020. From 1999 to 2023, 226,056 BTC deaths were recorded. Annual deaths increased from 6,121 to 13,637, and the AAMR increased from 4.37 to 6.10 per 100,000 (AAPC, 2.22%; 95% CI, 1.95%-2.50%; P < 0.001), with acceleration after 2007. The Non-Hispanic Black population exhibited the fastest increase in mortality among racial/ethnic groups, with an AAPC of 3.20%, whereas Hispanics had the highest AAMR in 2023. The 35-44-year age group showed the fastest increase despite low mortality (AAPC, 3.77%). In 2023, the Midwest had the highest AAMR, at 5.50 per 100,000, followed by the West at 5.32 per 100,000. In standardized urbanization-stratified data through 2020, metropolitan areas had a higher AAMR than nonmetropolitan areas (4.65 vs. 4.30 per 100,000). Subtype-specific analyses showed that intrahepatic cholangiocarcinoma accounted for the largest proportion of deaths (132,830; 58.76%) and had an increasing AAMR from 1.82 to 4.17 per 100,000, whereas gallbladder cancer accounted for 51,720 deaths (22.88%) and had a declining AAMR from 1.46 to 0.98 per 100,000. Extrahepatic bile duct cancer, ampulla of Vater cancer, and other/unspecified BTCs contributed 18,669, 5,135, and 17,702 deaths, respectively, highlighting that pooled BTC estimates may mask divergent subtype patterns. These opposite iCCA and GBC patterns supported separate subtype reporting rather than interpretation of the pooled BTC estimate alone in this study. BTC mortality among US adults aged ≥ 35 years increased from 1999 to 2023, with demographic, geographic, urbanization-related, and subtype-specific heterogeneity. These findings support subtype-aware surveillance, early detection, and equitable resource allocation.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about unspecified allergy vaccine